Capella

05 Oct, 2022 Alnylam Presents at OTS 2022 Annual Meeting

We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2022 18^th Annual Meeting held in Phoenix, Arizona on October 2-5, 2022.

Human Genetics as an Enabler of RNAi Therapeutics – Paul Nioi
Phase 3 study, HELIOS-A, in hATTR Patients Evaluating a Single Dose Regimen – Gabriel Robbie
Toxicology and DMPK Assessment of siRNA Therapeutics – Joe Dybowski

30 Sep, 2022 Results from APOLLO-B Phase 3 Study of Patisiran Presented as HFSA

At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Read the press release
Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”
Kale, et al. “Exploratory Analyses from APOLLO-B, a Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy”

27 Sep, 2022 RNAi Roundtable: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases

On September 27, 2022, we hosted an online RNAi Roundtable to review the progress with cemdisiran, an investigational RNAi therapeutic in development for the treatment of IgA nephropathy (IgAN) and other complement-mediated diseases.

Access the replay
View the presentation

22 Sep, 2022 New Analysis from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at IPNA

Results from a post-hoc analysis of patients on hemodialysis in the ongoing ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the International Pediatric Nephrology Association (IPNA) Congress (Sept. 7-11, 2022).

Michael, et al. “Relationship of Baseline Weight and Response to Lumasiran in Patients With Primary Hyperoxaluria Type 1 on Hemodialysis”

19 Sep, 2022 Ninth Annual RNAi Roundtable Series

We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as medical thought leaders, will review recent progress in a selection of our pipeline programs and platform innovations, and provide perspectives on clinical developments and unmet needs.

08 Sep, 2022 Results from APOLLO-B Phase 3 Study of Patisiran Presented at ISA

During a late-breaker session at the 18^th International Symposium on Amyloidosis, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Read the press release
Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”

29 Aug, 2022 New Results from Phase 2 Study of Investigational Cemdisiran Presented at EMCHD

During the 18^th European Meeting on Complement in Human Disease (EMCHD), taking place August 26-28, 2022, we presented new results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is being developed in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy.

Read the press release
Barratt, et al. “Results from the Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy”

02 Aug, 2022 ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology.

Read the paper in the Pediatric Nephrology

23 Jul, 2022 HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

Eighteen-month efficacy and safety results from the HELIOS-A Phase 3 study of AMVUTTRA™ (vutrisiran), an RNAi therapeutic recently approved in the U.S. for adults with the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, were published in Amyloid.

Read the paper in Amyloid

20 Jul, 2022 ILLUMINATE-C Phase 3 Results for Lumasiran Published in American Journal of Kidney Diseases

Results from the six-month primary analysis of the ongoing ILLUMINATE-C Phase 3 study of lumasiran in patients of all ages with primary hyperoxaluria type 1 (PH1) and advanced kidney disease were published online in the American Journal of Kidney Diseases.

Read the paper in the American Journal of Kidney Diseases